Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.

Park JI, Cho DH, Hahn SW, Jeong B, Kim JH, Kim SW, Koo MS, Lee SH, Lee SJ, Lee YH, Park JI, Rho SH, Chung YC.

Int Clin Psychopharmacol. 2014 Mar;29(2):77-85. doi: 10.1097/YIC.0000000000000005.

PMID:
23970176
2.

Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.

Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ; APLUS study group.

Psychiatry Clin Neurosci. 2009 Feb;63(1):73-81. doi: 10.1111/j.1440-1819.2008.01907.x.

3.

Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.

Zhao T, Park TW, Yang JC, Huang GB, Kim MG, Lee KH, Chung YC.

Int Clin Psychopharmacol. 2012 Jul;27(4):184-90. doi: 10.1097/YIC.0b013e3283528d22.

PMID:
22426471
4.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
5.

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.

Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.

J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.

PMID:
19230981
6.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.

Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31.

PMID:
17974864
7.

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.

Arch Gen Psychiatry. 2003 Jul;60(7):681-90.

PMID:
12860772
8.

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.

Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG.

J Clin Psychiatry. 2007 Jan;68(1):29-36.

PMID:
17284127
9.

Intramuscular aripiprazole in the acute management of psychomotor agitation.

De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, De Persis S, Piazzi G, Simonetti A, Telesforo CL, Sciarretta A, Caccia F, Gentile G, Kotzalidis GD, Girardi P.

Pharmacotherapy. 2013 Jun;33(6):603-14. doi: 10.1002/phar.1260. Epub 2013 Mar 15.

PMID:
23505124
10.

Trial of aripiprazole in the treatment of first-episode schizophrenia.

Lee HY, Ham BJ, Kang RH, Paik JW, Hahn SW, Lee MS, Lee MS.

Psychiatry Clin Neurosci. 2010 Feb;64(1):38-43. doi: 10.1111/j.1440-1819.2009.02039.x.

11.

A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.

Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:110-4. doi: 10.1016/j.pnpbp.2012.09.010. Epub 2012 Sep 27.

PMID:
23022672
12.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
13.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
14.

Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).

Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M.

J Clin Psychiatry. 2001 Aug;62(8):623-30.

PMID:
11561935
15.

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA.

J Clin Psychiatry. 2007 Jan;68(1):111-9.

PMID:
17284138
16.

Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.

Liu CC, Chien YL, Hsieh MH, Hwang TJ, Hwu HG, Liu CM.

J Clin Psychopharmacol. 2013 Feb;33(1):18-23. doi: 10.1097/JCP.0b013e31827cb017.

PMID:
23277261
17.

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.

J Clin Psychiatry. 2009 Jan;70(1):25-35. Epub 2008 Dec 2.

PMID:
19192472
18.
19.

Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.

De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, Iwamoto T.

J Clin Psychopharmacol. 2005 Oct;25(5):463-7. Erratum in: J Clin Psychopharmacol. 2005 Dec;25(6):560. Carson, William H [added]; Iwamoto, Taro [added].

PMID:
16160622
20.

Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.

Josiassen RC, Shaughnessy RA, Filymer DM, Donohue AM, Kacso M, Finkel N, Curtis J, Audino B, Skuban N.

Early Interv Psychiatry. 2010 Feb;4(1):57-63. doi: 10.1111/j.1751-7893.2010.00163.x.

PMID:
20199481

Supplemental Content

Support Center